Predicting Success of Allergen-Specific Immunotherapy

Area of Science:

• Immunology
• Allergy Research
• Immunotherapy

Background:

• Immunological tolerance is crucial for therapeutic interventions but not fully understood.
• Allergen immunotherapy (AIT) treats IgE-mediated airway diseases like allergic rhinitis and asthma.
• AIT offers specific, long-lasting symptom reduction and potential asthma prevention.

Purpose of the Study:

• To understand the mechanisms of AIT and identify therapy-guiding biomarkers.
• To explore the roles of cellular interactions (T, B, dendritic cells, macrophages, epithelial cells) in clinical tolerance.
• To investigate cellular responses and cytokine patterns for monitoring AIT progress.

Main Methods:

• Analysis of cellular responses and cytokine patterns during AIT.
• Assessment of type-2 immunity mediators (CCL-26, IL-4, IL-13) and type-1 mediators (interferon-gamma).
• Evaluation of tissue-homeostating factors like indoleamine 2,3-dioxygenase (IDO).

Main Results:

• Clinical improvement in AIT correlates with decreased effector cells and type-2 mediators.
• Increased type-1 mediators and IDO expression are associated with immune tolerance.
• Individual gene expression levels do not predict AIT outcomes on an individual level.

Conclusions:

• Monitoring cellular and cytokine changes provides insight into AIT mechanisms.
• Combinations or ratios of gene expression levels are promising for predictive biomarkers in AIT.
• Further research is needed to develop reliable biomarkers for personalized AIT.